(CercleFinance.com) – Sensorion on Monday unveiled new data from its phase 2a proof-of-concept clinical trial in ototoxicity induced by cisplatin, an anti-cancer drug.
These preliminary data show that SENS-401 has a favorable safety profile when administered continuously for up to eleven weeks in adult patients receiving cisplatin-based chemotherapy.
In a press release, Sensorion adds that recruitment is progressing well, with more than a third of the required population included in the study.
The biotechnology company plans to communicate progress from its Phase 2a proof-of-concept study at the World Audiology Congress, to be held in September 2024, in Paris.
As for the phase 2a study conducted on SENS-401 in the prevention of residual hearing loss after cochlear implantation, it is also progressing as planned, adds the company, which plans to complete the recruitment of its patients in early next year.
Following these announcements, Sensorion shares changed little (-0.1%) on Monday on the Paris Stock Exchange, after having gained up to 3% during the morning.